| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 26 | 2025 | 210 | 6.330 |
Why?
|
| Alzheimer Disease | 35 | 2026 | 1001 | 5.580 |
Why?
|
| tau Proteins | 17 | 2026 | 186 | 4.300 |
Why?
|
| Genetic Predisposition to Disease | 26 | 2025 | 734 | 3.260 |
Why?
|
| Drosophila Proteins | 14 | 2026 | 188 | 2.920 |
Why?
|
| Drosophila melanogaster | 12 | 2026 | 193 | 2.830 |
Why?
|
| Drosophila | 21 | 2026 | 152 | 2.610 |
Why?
|
| Genome-Wide Association Study | 24 | 2025 | 423 | 2.090 |
Why?
|
| Brain | 18 | 2026 | 1472 | 1.980 |
Why?
|
| Neurons | 16 | 2026 | 1263 | 1.640 |
Why?
|
| alpha-Synuclein | 8 | 2025 | 61 | 1.550 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2024 | 213 | 1.340 |
Why?
|
| Parkinsonian Disorders | 11 | 2024 | 42 | 1.330 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2025 | 863 | 1.210 |
Why?
|
| Aging | 10 | 2023 | 783 | 1.170 |
Why?
|
| Humans | 94 | 2026 | 43102 | 1.090 |
Why?
|
| Disease Models, Animal | 13 | 2026 | 1596 | 1.010 |
Why?
|
| Neurodegenerative Diseases | 4 | 2017 | 141 | 1.010 |
Why?
|
| Animals | 39 | 2026 | 16992 | 0.990 |
Why?
|
| Glucosylceramidase | 5 | 2023 | 6 | 0.990 |
Why?
|
| Genetic Loci | 6 | 2019 | 104 | 0.890 |
Why?
|
| Tauopathies | 3 | 2021 | 22 | 0.890 |
Why?
|
| Lysosomal Storage Diseases | 3 | 2019 | 3 | 0.860 |
Why?
|
| Lysosomes | 2 | 2023 | 86 | 0.800 |
Why?
|
| Neuronal Plasticity | 1 | 2024 | 126 | 0.800 |
Why?
|
| Cytoskeletal Proteins | 3 | 2024 | 116 | 0.790 |
Why?
|
| Synapses | 1 | 2024 | 185 | 0.790 |
Why?
|
| Mutation | 10 | 2026 | 1177 | 0.760 |
Why?
|
| Synaptic Transmission | 2 | 2020 | 149 | 0.750 |
Why?
|
| DNA Transposable Elements | 2 | 2018 | 55 | 0.690 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2021 | 6 | 0.690 |
Why?
|
| Male | 50 | 2026 | 23409 | 0.680 |
Why?
|
| Vesicular Transport Proteins | 2 | 2025 | 48 | 0.680 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2021 | 11 | 0.680 |
Why?
|
| Tremor | 1 | 2021 | 9 | 0.680 |
Why?
|
| Female | 55 | 2026 | 24698 | 0.680 |
Why?
|
| Genetic Variation | 7 | 2025 | 430 | 0.670 |
Why?
|
| Phenotype | 12 | 2026 | 780 | 0.670 |
Why?
|
| Postural Balance | 1 | 2021 | 37 | 0.660 |
Why?
|
| Lewy Bodies | 5 | 2021 | 30 | 0.660 |
Why?
|
| Aged, 80 and over | 25 | 2024 | 2853 | 0.650 |
Why?
|
| Endosomes | 1 | 2020 | 33 | 0.640 |
Why?
|
| Spliceosomes | 1 | 2019 | 10 | 0.620 |
Why?
|
| RNA Splicing | 1 | 2019 | 41 | 0.620 |
Why?
|
| 14-3-3 Proteins | 1 | 2019 | 21 | 0.620 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 72 | 0.600 |
Why?
|
| Aged | 33 | 2025 | 8214 | 0.600 |
Why?
|
| Nerve Degeneration | 1 | 2019 | 111 | 0.590 |
Why?
|
| Sphingomyelin Phosphodiesterase | 2 | 2019 | 9 | 0.590 |
Why?
|
| Nervous System Diseases | 2 | 2019 | 77 | 0.580 |
Why?
|
| Multiple System Atrophy | 1 | 2018 | 3 | 0.570 |
Why?
|
| Neurofibrillary Tangles | 2 | 2026 | 115 | 0.570 |
Why?
|
| Acid Ceramidase | 1 | 2017 | 1 | 0.550 |
Why?
|
| Organic Anion Transporters | 1 | 2017 | 6 | 0.550 |
Why?
|
| Cathepsin D | 1 | 2017 | 16 | 0.550 |
Why?
|
| Cognition Disorders | 6 | 2021 | 243 | 0.550 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2017 | 27 | 0.550 |
Why?
|
| Symporters | 1 | 2017 | 15 | 0.540 |
Why?
|
| Animals, Genetically Modified | 7 | 2023 | 100 | 0.540 |
Why?
|
| Cohort Studies | 14 | 2024 | 1759 | 0.480 |
Why?
|
| Prospective Studies | 12 | 2025 | 1600 | 0.470 |
Why?
|
| Emergency Service, Hospital | 4 | 2025 | 278 | 0.460 |
Why?
|
| Middle Aged | 27 | 2025 | 12222 | 0.460 |
Why?
|
| Cell Death | 1 | 2016 | 278 | 0.460 |
Why?
|
| Neurology | 1 | 2015 | 12 | 0.450 |
Why?
|
| Genomics | 3 | 2023 | 293 | 0.450 |
Why?
|
| Genome | 2 | 2018 | 149 | 0.450 |
Why?
|
| Fentanyl | 2 | 2024 | 16 | 0.440 |
Why?
|
| Genetic Association Studies | 6 | 2016 | 118 | 0.410 |
Why?
|
| Genotype | 12 | 2020 | 800 | 0.400 |
Why?
|
| Gene Regulatory Networks | 4 | 2026 | 149 | 0.400 |
Why?
|
| Suicide, Attempted | 3 | 2020 | 108 | 0.400 |
Why?
|
| Neuroglia | 2 | 2024 | 133 | 0.390 |
Why?
|
| DiGeorge Syndrome | 1 | 2013 | 49 | 0.380 |
Why?
|
| Poison Control Centers | 2 | 2024 | 6 | 0.380 |
Why?
|
| Databases, Genetic | 4 | 2019 | 103 | 0.370 |
Why?
|
| Disease Progression | 5 | 2024 | 667 | 0.350 |
Why?
|
| Adult | 21 | 2025 | 13872 | 0.340 |
Why?
|
| Case-Control Studies | 9 | 2025 | 1285 | 0.330 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 306 | 0.330 |
Why?
|
| Risk Factors | 15 | 2025 | 3994 | 0.310 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 590 | 0.310 |
Why?
|
| Apoptosis | 3 | 2012 | 1568 | 0.280 |
Why?
|
| Alleles | 7 | 2026 | 352 | 0.280 |
Why?
|
| Dementia | 2 | 2024 | 160 | 0.270 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 115 | 0.260 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 252 | 0.260 |
Why?
|
| RNA Interference | 3 | 2018 | 247 | 0.260 |
Why?
|
| Models, Biological | 3 | 2019 | 712 | 0.250 |
Why?
|
| Models, Genetic | 2 | 2025 | 183 | 0.240 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1063 | 0.240 |
Why?
|
| Hippocampus | 2 | 2024 | 594 | 0.240 |
Why?
|
| Age of Onset | 4 | 2020 | 114 | 0.240 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2026 | 34 | 0.240 |
Why?
|
| GTP Cyclohydrolase | 1 | 2025 | 5 | 0.240 |
Why?
|
| Mice | 6 | 2024 | 6644 | 0.240 |
Why?
|
| Dystonic Disorders | 1 | 2025 | 8 | 0.240 |
Why?
|
| Genetic Heterogeneity | 1 | 2025 | 11 | 0.240 |
Why?
|
| Dystonia | 1 | 2025 | 12 | 0.230 |
Why?
|
| Tramadol | 1 | 2024 | 3 | 0.230 |
Why?
|
| Mitochondria | 2 | 2022 | 523 | 0.220 |
Why?
|
| Drug Contamination | 1 | 2024 | 11 | 0.220 |
Why?
|
| Chloramines | 1 | 2024 | 2 | 0.220 |
Why?
|
| Chlorine | 1 | 2024 | 10 | 0.220 |
Why?
|
| Central Nervous System | 1 | 2025 | 152 | 0.220 |
Why?
|
| Gene Expression | 2 | 2026 | 701 | 0.220 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 515 | 0.210 |
Why?
|
| Referral and Consultation | 1 | 2025 | 142 | 0.210 |
Why?
|
| Medicine in Literature | 1 | 2004 | 2 | 0.210 |
Why?
|
| Literature, Modern | 1 | 2004 | 2 | 0.210 |
Why?
|
| Drama | 1 | 2004 | 2 | 0.210 |
Why?
|
| Physician-Patient Relations | 1 | 2025 | 148 | 0.210 |
Why?
|
| Patients | 1 | 2004 | 16 | 0.210 |
Why?
|
| Motor Activity | 2 | 2019 | 437 | 0.200 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 33 | 0.200 |
Why?
|
| Peptide Fragments | 3 | 2016 | 307 | 0.200 |
Why?
|
| Proteomics | 3 | 2021 | 378 | 0.200 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2023 | 6 | 0.200 |
Why?
|
| Membrane Proteins | 3 | 2016 | 561 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 719 | 0.190 |
Why?
|
| Astrocytes | 2 | 2024 | 244 | 0.180 |
Why?
|
| Burnout, Professional | 1 | 2021 | 31 | 0.170 |
Why?
|
| Mice, Knockout | 1 | 2024 | 1035 | 0.170 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 201 | 0.170 |
Why?
|
| Receptors, Complement 3b | 2 | 2011 | 4 | 0.170 |
Why?
|
| Naloxone | 3 | 2025 | 56 | 0.170 |
Why?
|
| Proteome | 2 | 2019 | 152 | 0.170 |
Why?
|
| Narcotic Antagonists | 3 | 2025 | 78 | 0.170 |
Why?
|
| Nerve Tissue Proteins | 3 | 2020 | 386 | 0.160 |
Why?
|
| United States | 7 | 2025 | 5205 | 0.160 |
Why?
|
| Haplotypes | 3 | 2016 | 197 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 20 | 0.160 |
Why?
|
| Long QT Syndrome | 1 | 2020 | 15 | 0.160 |
Why?
|
| Penetrance | 1 | 2020 | 7 | 0.160 |
Why?
|
| Lewy Body Disease | 1 | 2020 | 16 | 0.160 |
Why?
|
| Baclofen | 1 | 2019 | 9 | 0.160 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2019 | 14 | 0.160 |
Why?
|
| Cathepsin B | 1 | 2020 | 35 | 0.150 |
Why?
|
| Physicians | 1 | 2021 | 188 | 0.150 |
Why?
|
| Apolipoproteins E | 6 | 2017 | 138 | 0.150 |
Why?
|
| Age Factors | 4 | 2016 | 1154 | 0.150 |
Why?
|
| Energy Metabolism | 1 | 2020 | 187 | 0.150 |
Why?
|
| Self Concept | 1 | 2020 | 171 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2025 | 719 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2024 | 1003 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 1067 | 0.140 |
Why?
|
| Microglia | 1 | 2020 | 208 | 0.140 |
Why?
|
| Stillbirth | 1 | 2017 | 20 | 0.140 |
Why?
|
| Software | 1 | 2019 | 236 | 0.130 |
Why?
|
| Substantia Nigra | 2 | 2021 | 52 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 200 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 189 | 0.130 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 3 | 2012 | 4 | 0.130 |
Why?
|
| Tropomyosin | 1 | 2016 | 16 | 0.130 |
Why?
|
| Essential Tremor | 1 | 2016 | 3 | 0.130 |
Why?
|
| alpha Catenin | 1 | 2016 | 6 | 0.130 |
Why?
|
| Young Adult | 7 | 2024 | 5080 | 0.130 |
Why?
|
| Proteins | 2 | 2016 | 382 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 74 | 0.130 |
Why?
|
| Microelectrodes | 1 | 2016 | 22 | 0.120 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 2 | 0.120 |
Why?
|
| Electroretinography | 1 | 2016 | 21 | 0.120 |
Why?
|
| Child | 5 | 2026 | 3443 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2016 | 38 | 0.120 |
Why?
|
| Tenascin | 1 | 2016 | 5 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2016 | 91 | 0.120 |
Why?
|
| Vision, Ocular | 1 | 2016 | 43 | 0.120 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 140 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2016 | 54 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 160 | 0.120 |
Why?
|
| Molecular Chaperones | 1 | 2016 | 70 | 0.120 |
Why?
|
| Membrane Potentials | 1 | 2016 | 222 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2013 | 91 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 1070 | 0.120 |
Why?
|
| Atrophy | 2 | 2012 | 51 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2024 | 2544 | 0.110 |
Why?
|
| Verbal Learning | 1 | 2014 | 18 | 0.110 |
Why?
|
| Base Sequence | 1 | 2017 | 983 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 139 | 0.110 |
Why?
|
| Apolipoprotein E4 | 2 | 2013 | 67 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2014 | 77 | 0.110 |
Why?
|
| Harm Reduction | 1 | 2014 | 27 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2024 | 1621 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 1723 | 0.100 |
Why?
|
| Retina | 1 | 2016 | 289 | 0.100 |
Why?
|
| Integrins | 1 | 2013 | 54 | 0.100 |
Why?
|
| Cognition | 3 | 2016 | 473 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2017 | 392 | 0.100 |
Why?
|
| Locus Coeruleus | 1 | 2012 | 17 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2013 | 47 | 0.100 |
Why?
|
| Brain Mapping | 1 | 2013 | 137 | 0.100 |
Why?
|
| Time Perception | 1 | 2012 | 9 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 78 | 0.090 |
Why?
|
| Period Circadian Proteins | 1 | 2012 | 37 | 0.090 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 72 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 10 | 0.090 |
Why?
|
| Receptors, Complement | 1 | 2012 | 2 | 0.090 |
Why?
|
| Likelihood Functions | 2 | 2025 | 62 | 0.090 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Heterozygote | 2 | 2026 | 110 | 0.090 |
Why?
|
| Selection, Genetic | 1 | 2012 | 75 | 0.090 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 333 | 0.090 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 2010 | 3 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 6081 | 0.080 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 20 | 0.080 |
Why?
|
| Endocytosis | 1 | 2011 | 118 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2014 | 363 | 0.080 |
Why?
|
| Neurofibrils | 1 | 2010 | 23 | 0.080 |
Why?
|
| Quantitative Trait Loci | 1 | 2011 | 88 | 0.080 |
Why?
|
| Clusterin | 1 | 2010 | 9 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 561 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 50 | 0.080 |
Why?
|
| Neurites | 1 | 2010 | 40 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2011 | 2157 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 199 | 0.080 |
Why?
|
| Peptides | 2 | 2003 | 372 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 236 | 0.080 |
Why?
|
| Protein Kinases | 3 | 2007 | 100 | 0.080 |
Why?
|
| HIV Infections | 1 | 2024 | 2586 | 0.080 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2016 | 95 | 0.080 |
Why?
|
| Prevalence | 2 | 2024 | 1612 | 0.080 |
Why?
|
| Neurogenesis | 2 | 2020 | 63 | 0.080 |
Why?
|
| Amyloid | 2 | 2024 | 65 | 0.070 |
Why?
|
| Species Specificity | 2 | 2020 | 286 | 0.070 |
Why?
|
| Herpes Zoster Oticus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Proline-Directed Protein Kinases | 1 | 2007 | 1 | 0.070 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2007 | 38 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2021 | 241 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 287 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 587 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 140 | 0.060 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 34 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 133 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 863 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2026 | 67 | 0.060 |
Why?
|
| Buprenorphine | 1 | 2025 | 51 | 0.060 |
Why?
|
| Disinfectants | 1 | 2024 | 8 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2024 | 44 | 0.050 |
Why?
|
| Piperidines | 1 | 2024 | 83 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2024 | 109 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2006 | 346 | 0.050 |
Why?
|
| Caenorhabditis elegans | 2 | 2017 | 80 | 0.050 |
Why?
|
| Synucleins | 1 | 2003 | 7 | 0.050 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Epithelium | 1 | 2003 | 78 | 0.050 |
Why?
|
| Transgenes | 1 | 2003 | 65 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 518 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 57 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 93 | 0.050 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 57 | 0.050 |
Why?
|
| Caregivers | 1 | 2025 | 197 | 0.050 |
Why?
|
| Microtubules | 1 | 2003 | 121 | 0.050 |
Why?
|
| Feedback, Physiological | 1 | 2002 | 32 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 490 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2002 | 57 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 495 | 0.040 |
Why?
|
| Rats | 2 | 2024 | 3735 | 0.040 |
Why?
|
| Chicago | 1 | 2021 | 31 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 532 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 282 | 0.040 |
Why?
|
| Emotions | 1 | 2024 | 254 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1175 | 0.040 |
Why?
|
| Independent Living | 1 | 2021 | 47 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2012 | 206 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 126 | 0.040 |
Why?
|
| Sample Size | 1 | 2020 | 28 | 0.040 |
Why?
|
| Quality of Life | 1 | 2025 | 616 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 182 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2024 | 1546 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 27 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2016 | 883 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 74 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 47 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2012 | 587 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 170 | 0.040 |
Why?
|
| Galactosylceramidase | 1 | 2019 | 1 | 0.040 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2019 | 1 | 0.040 |
Why?
|
| Sandhoff Disease | 1 | 2019 | 2 | 0.040 |
Why?
|
| Mucopolysaccharidosis III | 1 | 2019 | 2 | 0.040 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2019 | 3 | 0.040 |
Why?
|
| Niemann-Pick Diseases | 1 | 2019 | 3 | 0.040 |
Why?
|
| Gaucher Disease | 1 | 2019 | 3 | 0.040 |
Why?
|
| Proton-Translocating ATPases | 1 | 2019 | 17 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2020 | 185 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 280 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 258 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 32 | 0.030 |
Why?
|
| Diphenhydramine | 1 | 2017 | 5 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2018 | 30 | 0.030 |
Why?
|
| Gene Library | 1 | 2018 | 62 | 0.030 |
Why?
|
| Acetaminophen | 1 | 2017 | 30 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 58 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2018 | 352 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2013 | 986 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 592 | 0.030 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2016 | 3 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 102 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1009 | 0.030 |
Why?
|
| Detergents | 1 | 2016 | 25 | 0.030 |
Why?
|
| Iceland | 1 | 2016 | 5 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2016 | 20 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 2016 | 26 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 89 | 0.030 |
Why?
|
| Diagnosis | 1 | 2016 | 10 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2018 | 195 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 861 | 0.030 |
Why?
|
| COS Cells | 1 | 2016 | 68 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 704 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 48 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 139 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 94 | 0.030 |
Why?
|
| Protein Folding | 1 | 2016 | 123 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2007 | 462 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 256 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1857 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 327 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 66 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1271 | 0.030 |
Why?
|
| Sulfotransferases | 1 | 2014 | 9 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1081 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 652 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 509 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 49 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 972 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 665 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 11 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 20 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1078 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 15 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2013 | 51 | 0.020 |
Why?
|
| Serine | 1 | 2013 | 79 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2012 | 18 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 73 | 0.020 |
Why?
|
| Actigraphy | 1 | 2012 | 17 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1082 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2012 | 53 | 0.020 |
Why?
|
| Receptor, EphA1 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 145 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 35 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 7 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 355 | 0.020 |
Why?
|
| Autopsy | 1 | 2011 | 48 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 1772 | 0.020 |
Why?
|
| Secretory Pathway | 1 | 2011 | 6 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 284 | 0.020 |
Why?
|
| Glutamates | 1 | 2011 | 23 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2013 | 192 | 0.020 |
Why?
|
| Clathrin | 1 | 2011 | 21 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 150 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 224 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2011 | 114 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 101 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 11 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 110 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 118 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 296 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2011 | 115 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2013 | 273 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 277 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 223 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2010 | 136 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 575 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2011 | 403 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1604 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2013 | 735 | 0.020 |
Why?
|
| Alanine | 1 | 2007 | 34 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2007 | 35 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 159 | 0.020 |
Why?
|
| Eye | 1 | 2007 | 77 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 138 | 0.010 |
Why?
|
| Body Patterning | 1 | 2003 | 25 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2003 | 29 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 934 | 0.010 |
Why?
|
| Pupa | 1 | 2002 | 6 | 0.010 |
Why?
|
| Frizzled Receptors | 1 | 2002 | 3 | 0.010 |
Why?
|
| Epistasis, Genetic | 1 | 2002 | 19 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2002 | 30 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2002 | 53 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 154 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 146 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 314 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2002 | 93 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 508 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2002 | 206 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 1180 | 0.010 |
Why?
|